Clene Nanomedicine is a clinical-stage biopharmaceutical company co-founded in 2013 and focused on developing treatments for neurodegenerative disease. Its patented electro-crystal-chemistry process produces clean-surfaced nanocrystals, including the investigational gold-based candidate CNM-Au8 for people living with ALS.
CNM-Au8 federally registered trademark
Registration
Aclipse TherapeuticsAclipse Therapeutics is a clinical-stage biopharmaceutical company led by executives with experience taking drug candidates from research through regulatory development and commercial transactions. Its work centers on disease-modifying treatments for severe neuromuscular conditions, including M102 for ALS, using biological insights to identify patients most likely to respond.KING OF PRUSSIA, PA
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
NeuroNascent, IncFounded by neuroscientist Judith Kelleher-Andersson, NeuroNascent is a privately held biotechnology company developing oral small-molecule therapies designed to stimulate the brain’s own neuron regeneration. Its lead candidate, NNI-362, has completed Phase 1a safety testing in healthy older adults and is being advanced for Alzheimer’s and Parkinson’s disease, while the company’s patented discovery platform also supports programs in other neurological disorders. The Clarksville, Maryland company is led by a team with deep experience in central nervous system drug development.CLARKSVILLE, MD
Neuraly IncFounded by drug-delivery researcher Seulki Lee after research with Johns Hopkins scientists, Neuraly is a clinical-stage biotechnology company developing medicines for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Its research centers on glial biology and neuroinflammation, with lead candidate NLY01 advancing through Phase 2 after showing neuroprotective effects in preclinical models. Neuraly operates as a subsidiary of D&D Pharmatech and is guided by scientific co-founders from Johns Hopkins University.GAITHERSBURG, MD